Company / Working Capital
Travere Therapeutics, Inc. Working Capital History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$277.7M
FY2025
5-year range
$216.0M / $458.7M
FY2021-FY2025
Trend
+28.6%
vs FY2024
Sector context
#150 of 213
Health Care
What the data says
At $278M, Travere Therapeutics, Inc.'s working capital ranks #150 of 213 in the Health Care sector. Working Capital has fluctuated over the past 10 years, ranging from $216M in FY2024 to $459M in FY2021.
Based on SEC 10-K filings.
$278M in FY2025 with a 5-year CAGR of -2.7%.
Declined from $439M to $278M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- -6.9%
- 5-Year CAGR
- -2.7%
- 10-Year CAGR
- -
Sector benchmark
#150 of 213 in Health CareTop 70% of 213This company $277.7M Sector average $934.6M
▼
-70.3% below sector average
Key checks
Key Insights
- 5-year CAGR of -2.7%, indicating a declining trend.
- In FY2025, working capital increased 28.6% year-over-year.
- Ranks #150 out of 213 companies in the Health Care sector.
- Peak working capital was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $277.7M | +28.6% |
| FY2024 | $216.0M | -50.8% |
| FY2023 | $438.9M | +27.5% |
| FY2022 | $344.3M | -25.0% |
| FY2021 | $458.7M | +44.4% |
| FY2020 | $317.7M | -4.8% |
| FY2019 | $333.6M | -14.7% |
| FY2018 | $391.1M | +62.8% |
| FY2017 | $240.1M | -3.6% |
| FY2016 | $249.1M | +15.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026